- Home
- TOYO vs LPTX Comparison
TOYO vs LPTX Comparison
Compare TOYO & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOYO
- LPTX
- Stock Information
- Founded
- TOYO 2022
- LPTX 2011
- Country
- TOYO Japan
- LPTX United States
- Employees
- TOYO N/A
- LPTX N/A
- Industry
- TOYO
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TOYO
- LPTX Health Care
- Exchange
- TOYO NYSE
- LPTX Nasdaq
- Market Cap
- TOYO 115.2M
- LPTX 117.1M
- IPO Year
- TOYO N/A
- LPTX N/A
- Fundamental
- Price
- TOYO $3.04
- LPTX $2.74
- Analyst Decision
- TOYO
- LPTX Strong Buy
- Analyst Count
- TOYO 0
- LPTX 4
- Target Price
- TOYO N/A
- LPTX $8.63
- AVG Volume (30 Days)
- TOYO 23.4K
- LPTX 452.0K
- Earning Date
- TOYO 08-21-2024
- LPTX 11-13-2024
- Dividend Yield
- TOYO N/A
- LPTX N/A
- EPS Growth
- TOYO N/A
- LPTX N/A
- EPS
- TOYO 0.76
- LPTX N/A
- Revenue
- TOYO $200,455,385.00
- LPTX N/A
- Revenue This Year
- TOYO N/A
- LPTX N/A
- Revenue Next Year
- TOYO N/A
- LPTX N/A
- P/E Ratio
- TOYO $3.97
- LPTX N/A
- Revenue Growth
- TOYO N/A
- LPTX N/A
- 52 Week Low
- TOYO $1.36
- LPTX $1.55
- 52 Week High
- TOYO $15.61
- LPTX $5.00
- Technical
- Relative Strength Index (RSI)
- TOYO N/A
- LPTX 39.77
- Support Level
- TOYO N/A
- LPTX $3.40
- Resistance Level
- TOYO N/A
- LPTX $3.61
- Average True Range (ATR)
- TOYO 0.00
- LPTX 0.40
- MACD
- TOYO 0.00
- LPTX -0.13
- Stochastic Oscillator
- TOYO 0.00
- LPTX 1.91
About TOYO TOYO CO LTD
Toyo Co Ltd along with its subsidiaries is engaged in research and development, production, and sales of solar cells.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .